@article{JTD23766,
author = {Melissa Bersanelli and Fausto Petrelli},
title = {Atezolizumab for first-line treatment of metastatic nonsquamous non-small cell lung cancer: what makes the difference?},
journal = {Journal of Thoracic Disease},
volume = {10},
number = {Suppl 26},
year = {2018},
keywords = {},
abstract = {The landing of immune checkpoint inhibitors (CKI) in the landscape of the primary treatment for non-small cell lung cancer (NSCLC) patients has been surely irrepressible, but burdened by a large selection limit, constituted by the percentage threshold of programmed death-ligand 1 (PD-L1) expression (1).},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/23766}
}